Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Axsome Therapeutics (AXSM) Inventory (2022 - 2026)

Axsome Therapeutics' Inventory history spans 5 years, with the latest figure at $31.5 million for Q1 2026.

  • On a quarterly basis, Inventory rose 93.12% to $31.5 million in Q1 2026 year-over-year; TTM through Mar 2026 was $31.5 million, a 93.12% increase, with the full-year FY2025 number at $27.9 million, up 77.59% from a year prior.
  • Inventory hit $31.5 million in Q1 2026 for Axsome Therapeutics, up from $27.9 million in the prior quarter.
  • Over the last five years, Inventory for AXSM hit a ceiling of $31.5 million in Q1 2026 and a floor of $4.3 million in Q4 2022.
  • Historically, Inventory has averaged $15.6 million across 5 years, with a median of $15.2 million in 2023.
  • The widest YoY moves for Inventory: up 250.35% in 2023, down 28.62% in 2023.
  • Tracing AXSM's Inventory over 5 years: stood at $4.3 million in 2022, then surged by 250.35% to $15.1 million in 2023, then increased by 3.94% to $15.7 million in 2024, then skyrocketed by 77.59% to $27.9 million in 2025, then rose by 12.8% to $31.5 million in 2026.
  • Business Quant data shows Inventory for AXSM at $31.5 million in Q1 2026, $27.9 million in Q4 2025, and $23.8 million in Q3 2025.